Indication

Fibrodysplasia ossificans progressiva

Fibrodysplasia ossificans progressiva is an ultra-rare, severely disabling autosomal dominant genetic disorder of the connective and musculoskeletal systems. Read more about Fibrodysplasia ossificans progressiva

3 drugs 3 manufacturers

Advertisement

Drugs that treat it

Common Fibrodysplasia ossificans progressiva therapies.

Showing 1–3 of 3 drugs

SOHONOS (palovarotene)

FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP) AGENTS·FIBRODYSPLASIA OSSIFICANS PROGRESSIVA
IPSEN BIOPHARMA

PASATRU (garetosmab-grts)

FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP) AGENTS·FIBRODYSPLASIA OSSIFICANS PROGRESSIVA
Regeneron Pharmaceuticals, Inc.
Filter & compare in the drug finder →Opens the drug finder with Fibrodysplasia ossificans progressiva preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Fibrodysplasia ossificans progressiva.

Fibrodysplasia ossificans progressiva is an ultra-rare, severely disabling autosomal dominant genetic disorder of the connective and musculoskeletal systems.

Most commonly caused by activating mutations in the *ACVR1* gene, the condition leads to dysregulated bone morphogenetic protein signaling that drives progressive, endochondral heterotopic ossification within skeletal muscle, tendons, ligaments, and fascia.

Clinically, affected individuals typically present at birth with characteristic congenital malformations of the great toes, followed in early childhood by episodic, painful soft-tissue flare-ups often triggered by minor trauma, intramuscular injections, or viral illness.

Over time, cumulative extraskeletal bone formation bridges joints across the axial and appendicular skeleton, culminating in progressive immobility, ankylosis, and life-threatening thoracic insufficiency.

Personalize your experience

Follow Fibrodysplasia ossificans progressiva and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it